Skip to content
Screener

Praxis Precision Medicines, Inc. PRAX Accretion (Amortization) of Discounts and Premiums, Investments

Accretion (Amortization) of Discounts and Premiums, Investments at other companies

Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$364K-16.5%
MapLight Therapeutics, Inc. logo
MapLight Therapeutics, Inc.MPLT
$814K+217%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX

Other financials

Income statement

See full
Revenue--100%
Operating income-$96.9M-27.4%
Net income-$83.7M-17.7%
EPS (diluted)-$2.87+13.3%

Balance sheet

See full
Cash & equivalents$474.8M+201%
Total debt$1.1M+44.0%
Total equity$1.3B+232%
Total assets$1.4B+207%

Cash flow

See full
Operating cash flow-$77.5M-41.8%
CapEx$245.0K+338%
Free cash flow-$77.8M-42.1%

Valuation

See full
Market cap$10.06B+963%
Enterprise value$9.58B+1,115%

Profitability

See full
Operating margin-3,927.5%-1,497pp
Net margin-3,658.5%-1,388pp
FCF margin-3,067.4%-1,030pp

Returns & leverage

See full
Return on equity-38.9%-10.3pp
Debt / equity0.0×
Current ratio15.7×+9.4×

Where this comes from

Reported directly by Praxis Precision Medicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.

The source filing: Praxis Precision Medicines, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 8:32 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001689548-26-000083
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Depreciation expense7293
Stock-based compensation expense28,42116,556
Non-cash operating lease expense516506
Amortization of premiums and discounts on marketable securities, net(1,344)(2,216)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets(2,188)6,917
Accounts payable(1,352)16,304
Accrued expenses(10,446)(4,806)

Item 1. Financial Statements (Unaudited)

FAQ

What is Praxis Precision Medicines, Inc.'s accretion (amortization) of discounts and premiums, investments?
Praxis Precision Medicines, Inc. (PRAX) reported accretion (amortization) of discounts and premiums, investments of $689K in Q2 2026.
How has Praxis Precision Medicines, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
Praxis Precision Medicines, Inc.'s accretion (amortization) of discounts and premiums, investments decreased by 30.2% year-over-year, from $987K to $689K.
What is the long-term trend for Praxis Precision Medicines, Inc.'s accretion (amortization) of discounts and premiums, investments?
Over 3 years (2021 to 2025), Praxis Precision Medicines, Inc.'s accretion (amortization) of discounts and premiums, investments has grown at a 19.8% compound annual growth rate (CAGR), from -$2.09M to $3.59M.
What does accretion (amortization) of discounts and premiums, investments mean?
This metric captures the non-cash adjustments to the carrying value of investment securities, such as the amortization of premiums or accretion of discounts. It reconciles the difference between the purchase price and the face value of debt instruments held by the company.

Ask your AI about Praxis Precision Medicines, Inc.'s accretion (amortization) of discounts and premiums, investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude